Problem: No noticeable effect Possible causes: Dose too low for your neurochemistry Product quality issues (underdosed or degraded) Timing not optimal for your sleep patterns Individual non-response to DSIP Solutions: Increase dose by 25-50% increments over several days Try a different vendor or batch Experiment with different timing windows If no response at 250mcg with confirmed quality product, DSIP may not work for you Problem: Initial effects that faded Possible causes: Tolerance development from excessive frequency Product degradation over time Changes in baseline sleep (improvement making DSIP less noticeable) Solutions: Take a 2-4 week break and reassess Check reconstitution date and prepare fresh solution Reduce frequency to prevent tolerance Consider whether improved sleep fundamentals may have reduced DSIP's relative impact Problem: Inconsistent results Possible causes: Variable timing or dosing Lifestyle factors interfering (stress, caffeine, irregular schedule) Injection technique inconsistency Solutions: Standardize protocol: same dose, same time, same technique Address confounding factors: caffeine cutoff 8+ hours before bed, consistent wake times Ensure consistent subcutaneous depth and injection sites Problem: Too much sedation or next-day grogginess Possible causes: Dose too high Timing too close to bedtime Interaction with other substances Solutions: Reduce dose by 25-50% Administer earlier in the evening (2-3 hours before bed) DSIP dosage compared to other sleep peptides Understanding how DSIP compares to other sleep-promoting peptides helps you choose the right tool for your situation
This difference could be particularly relevant in formulations designed to address environmental damage or photo-aging
Hands down, best Doctors office around
The Bottom Line Sermorelin may indirectly increase testosterone production by directly increases testosterone production by stimulating your body to create more human growth hormone (hGH)
Wambier Journal JAAD International (Journal of the American Academy of Dermatology) Year 2025 Study type Retrospective clinical study with blinded evaluation and AI-assisted assessment Sample size 7 male patients, ages 2855, Norwood-Hamilton IIIIV Full paper PubMed PMID 40225275 Full text (PMC) DOI: 10.1016/j.jdin.2025.01.012 Reviewed by: Esther Bodde Cosmetic & Medical Doctor (MD) Why This Research Matters This 2025 study is one of the first to combine three active ingredients minoxidil, dutasteride, and copper peptides delivered directly into the scalp using a medical-grade tattooing technique
